

Multiple Sclerosis (MS) Clinically Isolated Syndrome (CIS)

## A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
5 Countries

**Trial Identifier**  
NCT04998812 2021-000062-14  
MN42988

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.

**Hoffmann-La Roche**  
Sponsor

**Phase 4**  
Phase

---

**NCT04998812 2021-000062-14 MN42988**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
Female

**Age**  
>=18 Years & <= 40 Years

**Healthy Volunteers**  
No

---